PharmaTelevision - Tissue Therapies’ Novel Platform

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Tissue Therapies’ Novel Platform

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, Fintan Walton talks to Steven Mercer, CEO of Tissue Therapies. They begin with a discussion of the origin of the company, which was established to commercialise research developed at the Queensland University of Technology (QUT). Steven explains in detail the company’s platform technology, VitroGro®, its application in therapeutics and tissue culture media, and its versatility. The discussion then covers the worldwide sales and distribution agreement that Tissue Therapies made with Invitrogen in 2007, including the revenues that the company is entitled to from Invitrogen. The patent protection that applies to VitroGro is outlined, in particular the broadness of the cover of the family of patents. Steven then talks about a recombinant protein based on VitroGro technology being developed by the company for diabetic venous and pressure ulcers. The interview concludes with his ideas on VitroGro’s commercial potential.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origins of Tissue Therapies .

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here in Brisbane, Australia. On this show I have Steven Mercer, who is the CEO of Tissue Therapies based here in Brisbane, welcome to the show.

Steven Mercer:

Thank you.

Fintan Walton:

Steven Mercer, your company is obviously involved in tissue and particularly growth factors.

Steven Mercer:

Yes.

Fintan Walton:

Could you tell us a little bit first of all about the origins of the company when it was originally founded and how it has evolved?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Steven Mercer

CEO

Dr. Steven Mercer worked as a Managing Director of Mercy Tissue Engineering, a successful tissue engineering company with commercial operations in Melbourne and Singapore. He has had a successful career with multinational companies, including 6 years with Smith & Nephew as General Manager, Smith & Nephew Surgical, during which he successfully grew Smith & Nephew Surgical in terms of sales per employee, profit per employee and market share. Before that, Dr Steven Mercer had 7 years as a health industry specialist with IBM. In addition to Dr Steven Mercer 's extensive commercial experience in healthcare and biotechnology, he is a Registered Medical Practitioner (Australia and US) and a former Surgical Registrar. Among his commercial achievements, Dr Steven Mercer managed the commercialization of the first (Australian) Therapeutic Goods Administration (TGA)-approved human cell biotechnology laboratory in Australia, including securing the licensing of living cell implants for human use, and managing rapid growth in sales and profit derived from the facility.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Tissue Therapies

Tissue Therapies , is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications. The company has worldwide exclusive rights to commercialize VitroGro a platform technology developed by tissue engineering experts at Queensland University of Technology (QUT) for enhancing cell growth, protein expression and cell migration. VitroGro is a patented, defined, set of protein complexes that produce a high rate of cell replication, protein expression and cell migration, both in vitro and in vivo, without the use of fetal bovine serum (FBS) or serum derivatives. Based on the platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, tissue regeneration, integration of orthopedic and medical implants, and other applications such as cosmeceuticals. Tissue Therapies also provides cell culture reagents to enhance the growth of cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.